161 related articles for article (PubMed ID: 31262666)
1. Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.
Austin M; Quesenberry PJ; Ventetuolo CE; Liang O; Reagan JL
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):593-597. PubMed ID: 31262666
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of pulmonary hypertension in myelofibrosis.
Lopez-Mattei J; Verstovsek S; Fellman B; Iliescu C; Bhatti K; Hassan SA; Kim P; Gray BA; Palaskas NL; Grosu HB; Mamas MA; Faiz SA
Ann Hematol; 2020 Apr; 99(4):781-789. PubMed ID: 32076825
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms.
Ferrari A; Scandura J; Masciulli A; Krichevsky S; Gavazzi A; Barbui T
Eur J Haematol; 2021 Feb; 106(2):250-259. PubMed ID: 33135220
[TBL] [Abstract][Full Text] [Related]
4. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.
Mitra D; Kaye JA; Piecoro LT; Brown J; Reith K; Mughal TI; Sarlis NJ
Cancer Med; 2013 Dec; 2(6):889-98. PubMed ID: 24403262
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients.
Venton G; Turcanu M; Colle J; Thuny F; Chebrek S; Farnault L; Mercier C; Ivanov V; Fanciullino R; Suchon P; Jarrot PA; Aissi K; Roche P; Cautela J; Arcani R; Costello R
Eur J Intern Med; 2019 Oct; 68():71-75. PubMed ID: 31421946
[TBL] [Abstract][Full Text] [Related]
6. Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm.
Yaylali YT; Yilmaz S; Akgun-Cagliyan G; Kilic O; Kaya E; Senol H; Ozen F
Med Princ Pract; 2020; 29(5):486-491. PubMed ID: 32069470
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.
Tabarroki A; Lindner DJ; Visconte V; Zhang L; Rogers HJ; Parker Y; Duong HK; Lichtin A; Kalaycio ME; Sekeres MA; Mountantonakis SE; Heresi GA; Tiu RV
Leukemia; 2014 Jul; 28(7):1486-93. PubMed ID: 24406841
[TBL] [Abstract][Full Text] [Related]
8. Severe pulmonary hypertension in chronic idiopathic myelofibrosis.
Halank M; Marx C; Baretton G; Müller KM; Ehninger G; Höffken G
Onkologie; 2004 Oct; 27(5):472-4. PubMed ID: 15585978
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients].
Su T; Zhang PH; Xu ZF; Chen HS; Qin TJ; Zhang Y; Zhang HL; Fan LW; Pan LJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):378-82. PubMed ID: 22781796
[TBL] [Abstract][Full Text] [Related]
10. Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms.
Brabrand M; Hansen KN; Laursen CB; Larsen TS; Vestergaard H; Abildgaard N
Eur J Haematol; 2019 Mar; 102(3):227-234. PubMed ID: 30450659
[TBL] [Abstract][Full Text] [Related]
11. The underdiagnosis of pulmonary hypertension in myelofibrosis.
Thachil J
Am J Med; 2010 Jun; 123(6):e15; author reply e17. PubMed ID: 20569739
[No Abstract] [Full Text] [Related]
12. [Investigation and analysis for current situation and pathogenesis relevant to pulmonary hypertension].
Lei S; Tang D; Xu N; Wu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jun; 42(6):641-646. PubMed ID: 28690220
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival.
Gerges M; Gerges C; Pistritto AM; Lang MB; Trip P; Jakowitsch J; Binder T; Lang IM
Am J Respir Crit Care Med; 2015 Nov; 192(10):1234-46. PubMed ID: 26181215
[TBL] [Abstract][Full Text] [Related]
14. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.
Gianelli U; Vener C; Bossi A; Cortinovis I; Iurlo A; Fracchiolla NS; Savi F; Moro A; Grifoni F; De Philippis C; Radice T; Bosari S; Lambertenghi Deliliers G; Cortelezzi A
Mod Pathol; 2012 Sep; 25(9):1193-202. PubMed ID: 22627739
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.
Gupta R; Jamal F; Yang D; Chendri C; Aldoss I; Malki MA; Mei M; Salhotra A; Dobrin S; Tran M; Venkataraman K; Palmer J; Stein AS; Sandhu K; Khaled S; Aribi A; Marcucci G; Forman SJ; Snyder D; Nakamura R; Ali H; Pullarkat V
Bone Marrow Transplant; 2020 May; 55(5):877-883. PubMed ID: 31695170
[TBL] [Abstract][Full Text] [Related]
16. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM
Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
Wong KM; Atenafu EG; Kim D; Kuruvilla J; Lipton JH; Messner H; Gupta V
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1589-99. PubMed ID: 22531490
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary hypertension with massive megalosplenia: A case report.
Yi T; Ma W; Qiu J; Ding W
Medicine (Baltimore); 2019 Mar; 98(12):e14594. PubMed ID: 30896614
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy.
Ong KC; Geske JB; Hebl VB; Nishimura RA; Schaff HV; Ackerman MJ; Klarich KW; Siontis KC; Coutinho T; Dearani JA; Ommen SR; Gersh BJ
Eur Heart J Cardiovasc Imaging; 2016 Jun; 17(6):604-10. PubMed ID: 26922089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
